scholarly journals PDG108 CLINICAL OUTCOMES ON SWITCHING BETWEEN NEWER P2Y12 RECEPTOR INHIBITORS AND CLOPIDOGREL IN DUAL ANTIPLATELET THERAPY IN HONG KONG ACUTE CORONARY SYNDROME POPULATION USING REAL WORLD DATA

2019 ◽  
Vol 22 ◽  
pp. S614-S615
Author(s):  
A. Lam ◽  
B. Yan ◽  
V. Lee
Keyword(s):  
Acute Coronary Syndrome ◽  
Hong Kong ◽  
Clinical Outcomes ◽  
Antiplatelet Therapy ◽  
Real World ◽  
Dual Antiplatelet Therapy ◽  
P2y12 Receptor ◽  
Real World Data ◽  
World Data ◽  
Coronary Syndrome

Real-world application of currently available decision models for dual antiplatelet therapy duration in acute coronary syndrome

2018 ◽  
Vol 19 (6) ◽  
pp. 310-313
Author(s):  
Nuccia Morici ◽  
Enrico Piccinelli ◽  
Dario Brunelli ◽  
Alice Sacco ◽  
Giovanna Viola ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Antiplatelet Therapy ◽  
Real World ◽  
Dual Antiplatelet Therapy ◽  
Decision Models ◽  
Coronary Syndrome ◽  
Real World Application

Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry

Angiology ◽  
2019 ◽  
Vol 71 (3) ◽  
pp. 235-241 ◽  
Author(s):  
Plinio Cirillo ◽  
Luigi Di Serafino ◽  
Vittorio Taglialatela ◽  
Paolo Calabrò ◽  
Emilia Antonucci ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Clinical Outcome ◽  
Antiplatelet Therapy ◽  
Medical Therapy ◽  
Real World ◽  
Dual Antiplatelet Therapy ◽  
Optimal Medical Therapy ◽  
Cerebrovascular Event ◽  
Coronary Syndrome ◽  
The Impact

Optimal medical therapy (OMT) at discharge is recommended after acute coronary syndrome (ACS). Few studies report the impact of OMT on long-term clinical outcome in a real-world scenario. We evaluated the impact of discharge OMT on top of dual-antiplatelet therapy (DAPT) on clinical outcome in the real-world ACS population of the Survey on anTicoagulated pAtients RegisTer ANTIPLATELET registry. The primary end point was major adverse cardiac and cerebrovascular event (MACCE), a composite of death, myocardial infarction, stroke, or target vessel revascularization. The co-primary end point was net adverse cardiac and cerebrovascular event (NACE), based on MACCE plus major bleeding. Consecutive patients with ACS with 1-year follow-up were enrolled. They were evaluated at discharge for the use of a β-blocker, angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers and statins. Optimal medical therapy was defined as the use of ≥2 of 3 medications. At multivariate analysis, both MACCE and NACE were significantly higher in non-OMT patients than in OMT patients (MACCE 18 [19] vs 59 [9], hazard ratio [HR] = 0.44 [0.26-0.75], P = .002, NACE 19 [20] vs 67 [10], HR = 0.47 [0.28-0.79], P = .004). In this real-world scenario, OMT at discharge on top of DAPT seems associated with a better clinical outcome compared with patients discharged on non-OMT.

scholarly journals P6028Antiplatelet therapy in acute coronary syndrome associated with renal impairment. Real world data

2018 ◽  
Vol 39 (suppl_1) ◽  
Author(s):  
A Izquierdo Bajo ◽  
M Almendro Delia ◽  
T Seoane-Garcia ◽  
L Madrona Jimenez ◽  
M Garcia Del Rio ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Renal Impairment ◽  
Real World ◽  
Real World Data ◽  
World Data ◽  
Coronary Syndrome
Sign in / Sign up

Export Citation Format

Share Document